Cure Kids is delighted to announce the appointment of Matthew McMahon to Chief Investment Manager of Cure Kids Ventures. Matthew is a highly skilled operator and analyst with a comprehensive technology strategy and finance background. He is known for his focus on advising on mergers, acquisitions, and venture capital.
Matthew has held several executive roles in technology companies in New Zealand. Most recently, he was GM of Commercialisation at WaikatoLink, the University of Waikato’s commercialisation office. During his time there, Matthew oversaw a pipeline of technology commercialisation projects. He also worked as a strategic partner with business owners and the founders of start-up organisations to develop and progress ideas and commercial operations.
First Watch Ltd is one of the projects developed from the research phase to a fully operational company. First Watch provides cyber security solutions and consulting services to manufacturing and industrial businesses. Matthew secured $7 million of equity investment, supported the development of recruitment strategies and product vision, and managed the first year of product development.
As the Chief Investment Manager of Cure Kids Ventures, Matthew is committed to helping the organisation grow its already-impressive portfolio of companies.
“Cure Kids Ventures has a strong track record of providing seed funding to companies with products and services covering medical devices, medications, diagnostics, health information and healthcare delivery systems, each with potential benefits for child health. I look forward to growing our reputation by continuing the good work,” says Matthew.
The Cure Kids Ventures team of Matthew McMahon and Michael Innes, Investment Analyst, is well supported by a board of experienced investment and health professionals who remain committed to supporting the organisation’s ongoing development.